Reduction of hepatitis b surface antigen may be more significant in pegylated interferon-alpha therapy combined with nucleotide analogues than combined with nucleoside analogues in chronic hepatitis b patients: a propensity score matching study

HIGHLIGHTS

• who: Yiran Xie et al. from the Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Fudan University, Shanghai, China have published the research work: Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study, in the Journal: Canadian Journal of Gastroenterology and Hepatology of 11/05/2022
• what: Before a new generation of efective drugs is introduced and popularized, exploration of the combination . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.